Open AccessAlectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
Author(s) -
Pietro Di Marino,
Gianluca Mannetta,
Consiglia Carella,
Antonino Grassadonia,
Nicola Tinari,
Clara Natoli,
Michele De Tursi
Publication year - 2020
Publication title -
international medical case reports journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.198
H-Index - 11
ISSN - 1179-142X
DOI - 10.2147/imcrj.s229080
Subject(s) - crizotinib , alectinib , anaplastic lymphoma kinase , medicine , tyrosine kinase inhibitor , pathology , lung cancer , oncology , cancer , malignant pleural effusion
Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase ( ALK ) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment.